Study of the Efficacy of Sulforaphane in Children Aged 6 to 12 With Attention Deficit Disorder With or Without Hyperactivity (SulfoTDAH)
ADHD is a neurodevelopmental disorder. It is the most common neurodevelopmental disorder in children and adolescents. Its prevalence is estimated at 5.9% in this population. The symptoms of ADHD combine attention deficit with behavioural disorders such as hyperactivity and impulsivity. Current treatment for ADHD is based on psychotherapeutic and psychoeducational measures aimed at improving behaviour and its impact on the family, social and school environment. Drug treatments may also be used, depending on the impact of the disorder and the effectiveness of alternative treatments. Psychostimulants such as amphetamine derivatives and methylphenidate are around 80% effective.
Sulforaphane is an active substance derived from broccoli that has already been tested in the treatment of other neurodevelopmental disorders. The main hypothesis is that sulforaphane is effective in treating the symptoms of Attention Deficit Disorder with or without Hyperactivity (ADHD) in children.
Tutkimuksen yleiskatsaus
Yksityiskohtainen kuvaus
This is a randomised controlled trial with a double-blind control group. The aim is to test the efficacy of Sulforaphane versus placebo by comparing these two groups with a 1:1 ratio.
The primary objective is to evaluate the efficacy of sulforaphane treatment versus placebo on the total inattention and hyperactivity/impulsivity score measured by the ADHD-RS scale (parents) at 8 weeks in children aged 6 to 12 years suffering from ADHD.
The primary endpoint was the ADHD-RS parent inattention and hyperactivity/impulsivity score at 8 weeks.
Secondary objectives:
To assess the efficacy of sulforaphane treatment versus placebo at 2, 4 and 8 weeks in children aged 6-12 years with ADHD on:
- Inattention and hyperactivity/impulsivity symptoms assessed by parents using the ADHD-RS;
- Social interactions using the SRS scale (Social Responsiveness Scale);
- Emotional dysregulation using the SDQ (Strength and Difficulties Questionnaire);
- Global functioning using the CGI-S (Clinical Global Impression - Severity) and the CGI-I (Clinical Global Impression - Improvement).
To assess the effect of treatment with sulforaphane versus placebo on attention and inhibition at 4 and 8 weeks: using a specific neuropsychological assessment: CPT (Continuous Performance Test); symptoms of inattention and hyperactivity/impulsivity assessed by the teacher using the ADHD-RS self-questionnaire. Differences in behaviour may be observed depending on the context (school versus family). It is therefore important to have 2 sources of information for the ADHD-RS questionnaire: the parents and the teacher.
To assess the tolerability of treatment with sulforaphane from a clinical point of view (use of a PAERS (Paediatrician Adverse Events Rating Scale) and a biological point of view (blood count, AST, ALT, total and conjugated bilirubin, blood ionogram, urea, creatininemia, T4, TSH).
The subgroup of patients included in the Robert Debré Hospital will have a High Resolution Electroencephalogram (HR-EEG) in order to study the electroencephalographic markers of response to treatment with sulforaphane.
An interview to assess interest in and satisfaction with the treatment will be conducted with the parents (Robert Debré) and the child in the month following the end of the study as part of a qualitative study.
Opintotyyppi
Ilmoittautuminen (Arvioitu)
Vaihe
- Ei sovellettavissa
Yhteystiedot ja paikat
Opiskeluyhteys
- Nimi: Eric ACQUAVIVA, PhD
- Puhelinnumero: +33 0140034092
- Sähköposti: eric.acquaviva@aphp.fr
Opiskelupaikat
-
-
-
Paris, Ranska, 75019
- Rekrytointi
- Robert Debre Hospital
-
Ottaa yhteyttä:
- Eric ACQUAVIVA, MD, PhD
- Puhelinnumero: +3340034092
- Sähköposti: eric.acquaviva@aphp.fr
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
Hyväksyy terveitä vapaaehtoisia
Sukupuolet, jotka voivat opiskella
Kuvaus
Inclusion Criteria:
- Children aged 6 to 12
- Diagnosis of ADHD according to DSM-5 criteria (Diagnostic and Statistical Manual of Mental Disorders)
- Followed or hospitalised in an investigating centre
- Consent of holders of parental authority
- Patient covered by health insurance (social security or CMU)
- Patients able to swallow capsules
Exclusion Criteria:
- Allergy to broccoli
- Psychotropic treatment including methylphenidate in the month prior to inclusion
- Ongoing psychotherapeutic and/or psycho-educational treatment specific to ADHD
- ASD (Autism Spectrum Disorder) according to DSM-5 criteria, intellectual disability (IQ< 80)
- Chronic neurological disease, epilepsy
- Holders of parental authority under guardianship or curatorship
- Previous intake of sulforaphane
- Known hypothyroidism or current thyroid treatment
- Participation in other interventional research involving the human person or being within the exclusion period following previous research involving the human person, where applicable
- Patient under AME (state medical aid)
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Hoito
- Jako: Satunnaistettu
- Inventiomalli: Rinnakkaistehtävä
- Naamiointi: Nelinkertaistaa
Aseet ja interventiot
Osallistujaryhmä / Arm |
Interventio / Hoito |
|---|---|
|
Kokeellinen: Sulforaphane
Prostaphane® is a dietary supplement based on SULFODYNE®, a broccoli seed extract standardised in free, stabilised sulforaphane. Patients will receive treatment for 8 weeks at the following dosage:
Each capsule contains 10mg of Sulforaphane. |
taken once a day (one to three capsules a day depending on the patient's weight) for 8 weeks of Sulforaphane |
|
Placebo Comparator: Placebo
Patients will receive treatment for 8 weeks at the following dosage:
Each capsule contains placebo. |
taken once a day (one to three capsules a day depending on the patient's weight) for 8 weeks of placebo |
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Inattention scores in ADHD-RS parents
Aikaikkuna: 8 weeks
|
Inattention scores in ADHD-RS (Attention Deficit Hyperactivity Disorder Rating Scale) parents |
8 weeks
|
|
Hyperactivity/impulsivity scores in ADHD-RS parents
Aikaikkuna: 8 weeks
|
Hyperactivity/impulsivity scores in ADHD-RS (Attention Deficit Hyperactivity Disorder Rating Scale) parents |
8 weeks
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Inattention scores in ADHD-RS parents
Aikaikkuna: 2, 4 and 12 weeks
|
Inattention scores in ADHD-RS (Attention Deficit Hyperactivity Disorder Rating Scale) parents |
2, 4 and 12 weeks
|
|
Hyperactivity/impulsivity scores in ADHD-RS parents
Aikaikkuna: 2, 4 and 12 weeks
|
Hyperactivity/impulsivity scores in ADHD-RS (Attention Deficit Hyperactivity Disorder Rating Scale) parents |
2, 4 and 12 weeks
|
|
Social Responsiveness Scale (SRS) scores and sub-scores
Aikaikkuna: 4, 8 and 12 weeks
|
Social Responsiveness Scale (SRS) scores and sub-scores |
4, 8 and 12 weeks
|
|
Strength and Difficulties Questionnaire (SDQ) emotional dysregulation sub-score
Aikaikkuna: 2, 4, 8 and 12 weeks
|
Strength and Difficulties Questionnaire (SDQ) emotional dysregulation sub-score |
2, 4, 8 and 12 weeks
|
|
Sustained attention and inhibition scores in the CPT (Continuous Performance Test)
Aikaikkuna: 4 and 8 weeks
|
Sustained attention and inhibition scores in the CPT (Continuous Performance Test) |
4 and 8 weeks
|
|
CGI-S (Clinical Global Impression - Severity) score
Aikaikkuna: 4 and 8 weeks
|
CGI-S (Clinical Global Impression - Severity) score |
4 and 8 weeks
|
|
CGI-I (Clinical Global Impression - Improvement) score
Aikaikkuna: 4 and 8 weeks
|
CGI-I (Clinical Global Impression - Improvement) score |
4 and 8 weeks
|
|
ADHD-RS teacher inattention and hyperactivity/impulsivity scores
Aikaikkuna: 4 and 8 weeks
|
ADHD-RS teacher inattention and hyperactivity/impulsivity scores |
4 and 8 weeks
|
|
tolerance of treatment: Adverse events score: PAERS (Paediatrician Adverse Events Rating Scale)
Aikaikkuna: 4 and 8 weeks
|
tolerance of treatment: Adverse events score: PAERS (Paediatrician Adverse Events Rating Scale) |
4 and 8 weeks
|
|
tolerance of treatment: Blood sample: Blood count
Aikaikkuna: 8 weeks
|
tolerance of treatment: Blood sample: Blood count |
8 weeks
|
|
tolerance of treatment: Blood sample: ASAT (Aspartate aminotransferase)
Aikaikkuna: 8 weeks
|
tolerance of treatment: Blood sample: ASAT (Aspartate aminotransferase) |
8 weeks
|
|
tolerance of treatment: Blood sample: ALAT (Alanin aminotransferase)
Aikaikkuna: 8 weeks
|
tolerance of treatment: Blood sample: ALAT (Alanin aminotransferase) |
8 weeks
|
|
tolerance of treatment: Blood sample: total bilirubin
Aikaikkuna: 8 weeks
|
tolerance of treatment: Blood sample: total bilirubin |
8 weeks
|
|
tolerance of treatment: Blood sample: conjugated bilirubin
Aikaikkuna: 8 weeks
|
tolerance of treatment: Blood sample: conjugated bilirubin |
8 weeks
|
|
tolerance of treatment: Blood sample: ionogram
Aikaikkuna: 8 weeks
|
tolerance of treatment: Blood sample: ionogram |
8 weeks
|
|
tolerance of treatment: Blood sample: urea
Aikaikkuna: 8 weeks
|
tolerance of treatment: Blood sample: urea |
8 weeks
|
|
tolerance of treatment: Blood sample: creatinine
Aikaikkuna: 8 weeks
|
tolerance of treatment: Blood sample: creatinine |
8 weeks
|
|
tolerance of treatment: Blood sample: T4
Aikaikkuna: 8 weeks
|
tolerance of treatment: Blood sample: T4 |
8 weeks
|
|
tolerance of treatment: Blood sample: TSH
Aikaikkuna: 8 weeks
|
tolerance of treatment: Blood sample: TSH |
8 weeks
|
|
Robert Debré patients: EEG-HR (High Resolution Electroencephalogram)
Aikaikkuna: 4 and 8 weeks
|
the criterion used will be the theta-beta ratio. |
4 and 8 weeks
|
|
Robert Debré patients: qualitative study:
Aikaikkuna: one month post treatment
|
The exploration criterion will be an in-depth description of the experience of the families and the child with regard to treatment with sulforaphane (interest and satisfaction). |
one month post treatment
|
Yhteistyökumppanit ja tutkijat
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Todellinen)
Ensisijainen valmistuminen (Arvioitu)
Opintojen valmistuminen (Arvioitu)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Todellinen)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Avainsanat
Muita asiaankuuluvia MeSH-ehtoja
Muut tutkimustunnusnumerot
- APHP230862
Yksittäisten osallistujien tietojen suunnitelma (IPD)
Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .